Gilead Sciences (GILD) Announces Topline Selonsertib Phase 2 Data in NASH; Anti-Fibrotic Activity Noted

October 20, 2016 10:06 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Gilead Sciences, Inc. (Nasdaq: GILD) announced the top-line results from three Phase 2 studies of GS-4997 (selonsertib), an investigational inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in nonalcoholic steatohepatitis (NASH), pulmonary arterial hypertension (PAH) and diabetic kidney disease (DKD). GS-4997 demonstrated anti-fibrotic activity in an open-label Phase 2 clinical trial that included 72 patients with NASH and moderate to severe (F2-F3) liver fibrosis, who received treatment with GS-4997 (18 mg or 6 mg orally once daily) alone or in combination with simtuzumab (SIM), an investigational antibody directed against lysyl oxidase-like-2 (LOXL2), or SIM alone (125 mg administered via weekly subcutaneous injections) for 24 weeks. Top-line efficacy data for fibrosis-related endpoints from 67 evaluable patients are summarized in the table below. Complete results will be presented at The Liver Meeting® 2016 in Boston.

Endpoint (Week 24)

GS-4997 18 mg± SIM

GS-4997 6 mg± SIM


Fibrosis Improvement ≥1 Stage from Baseline* 43% (n=13/30) 30% (n=8/27) 20% (n=2/10)
Progression to Cirrhosis

3% (n=1/30)

7% (n=2/27)

20% (n=2/10)

*Fibrosis staged according to the NASH Clinical Research Network (CRN) classification by a central pathologist blinded to treatment group.

Overall, GS-4997 was well tolerated with no dose-related increase in the incidence of treatment-emergent adverse events or serious adverse events. The most common adverse events were headache, nausea and sinusitis.

“We are committed to advancing our pipeline of investigational molecules that separately target metabolic dysfunction, inflammation and/or fibrosis associated with NASH,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “We are encouraged by these data demonstrating the anti-fibrotic effect of GS-4997 in patients with NASH after only 24 weeks of treatment, and look forward to sharing the complete results with the hepatology community. Additionally, pending discussions with regulatory agencies, we plan to initiate a Phase 3 clinical trial program of GS-4997 in patients with NASH.”

Separately, a Phase 2 study of GS-4997 in PAH did not achieve its primary endpoint and a Phase 2 study in DKD did not achieve its primary endpoint based on a preliminary analysis. Due to insufficient evidence of efficacy, Gilead has decided not to pursue Phase 3 studies of GS-4997 in PAH or DKD at this time. Data from these studies will be submitted for presentation at upcoming scientific conferences.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments

Related Entities


Add Your Comment